An impressive data set on progressive free survival (PFS) demonstrated by Roche's IMpower150 study in non-squamous non-small cell lung cancer (NSCLC) was nonetheless overshadowed at the American Association for Cancer Research (AACR) meeting April 16 by rival trial presentations - and observers say the jury will remain out about IMpower150's four-drug regime until overall survival data is presented later this year.
An updated analysis from Roche’s IMpower150 showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapies carboplatin and paclitaxel significantly improved progression-free...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?